Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: Intracellular loading and kinetics of presentation

Journal of Immunology

Volumn 167, Issue 5, 2001, Pages 2529-2537

  Luft, T ^a   Rizkalla, M ^a   Tsin Yee Tai, ^a   Chen, Q ^a   MacFarlan, R I ^a   Davis, I D ^a   Maraskovsky, E ^a   Cebon, J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BREFELDIN A; CARRIER PROTEIN; CYCLOHEXIMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELAN A; PROTEIN SYNTHESIS INHIBITOR; SYNTHETIC PEPTIDE; TAP PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MATURATION; CELL MEMBRANE TRANSPORT; CELL SURFACE; CONTROLLED STUDY; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; MEMBRANE VESICLE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; TRANSPORT KINETICS;

EID: 0035451352     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.5.2529     Document Type: Article

References (23)

1. Cancer vaccines
2. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor-infiltrating lymphocytes
3. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
4. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
5. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
6. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
7. Stringent allele/epitope requirements for MART-Melan A immunodominance: Implications for peptide-based immunotherapy
8. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
9. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice
10. The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes: Implications for understanding the degradative mechanism and antigen presentation
11. The cleavage preference of the proteasome governs the yield of antigenic peptides
12. HLA-A2.I-associated peptides from a mutant cell line: A second pathway of antigen presentation
13. Misfolded major histocompatibility complex class I molecules accumulate in an expanded ER-Golgi intermediate compartment
14. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells
15. Differential stability of antigenic MHC class I-restricted synthetic peptides
16. Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells
17. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
18. + progenitor cells
19. Peptide-receptive class 1 major histocompatibility complex molecules on TAP-deficient and wild-type cells and their roles in the processing of exogenous antigens
20. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
21. Type I IFNs enhance the terminal differentiation of dendritic cells
22. Adjuvant activity of iscoms; Effect of ratio and co-incorporation of antigen and adjuvant
23. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA